Results 51 to 60 of about 127,689 (285)

Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis

OncoTargets and Therapy, 2017
Immunotherapy based on cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells (CIK/DC-CIK) showed promising clinical outcomes for treating esophageal cancer (EC). However, the clinical benefit varies among previous studies.
Yan Liu, Ying Mu, Anqi Zhang, Shaoda Ren, Weihua Wang, Jiaping Xie, Yingxin Zhang, Changhui Zhou   +7 more
openaire   +4 more sources

Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy

Haematologica, 2013
Invariant natural killer T cells recognize glycolipid antigens such as α-galactosylceramide presented by CD1d. In preclinical models of B-cell malignancies, α-galactosylceramide is an adjuvant to tumor vaccination, enhancing tumor-specific T-cell ...
Robert Weinkove, Collin R. Brooks, John M. Carter, Ian F. Hermans, Franca Ronchese   +4 more
doaj   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer

Cell Death and Disease, 2022
Herein, Liu and colleagues show that CD4+ T cells in cytokine-induced killer (CIK) cells are required to enhance the clinical efficacy of CIK therapy. In addition, CD4+ T cells help via IL-17A production is critical to restoring the function of CD8+/CD3 ...
Shaochuan Liu, Yuan Meng, Liang Liu, Yingge Lv, Wenwen Yu, Ting Liu, Limei Wang, Di Mu, Qiuru Zhou, Min Liu, Yulin Ren, Dong Zhang, Baihui Li, Qian Sun, Xiubao Ren   +14 more
doaj   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Researche Advances on CIK Cells and Their Clinical Use in Lung Cancer

Chinese Journal of Lung Cancer, 2011
As the leading cause of cancer-related death among human beings, lung cancer seriously threats peoples’ health all over the world. Cytokine-induced killer cells (CIK) is a new kind of adaptive immune cells characterized by its dramatic proliferation ...
Hu LUO, Xiangdong ZHOU
doaj   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape.

, 2020
Multiple modalities for lung cancer therapy have emerged in the past decade, whereas their clinical applications and survival-beneficiary is little known. Vaccination with dendritic cells (DCs) or DCs/cytokine-induced killer (CIK) cells has shown limited
Mohsenzadegan, Monireh, Peng, Ren-Wang, Monireh Mohsenzadegan, Roudi, Raheleh, Raheleh Roudi, Ren‐Wang Peng   +5 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Efficacy of cytokine‑induced killer cells targeting CD40 and GITR

Oncology Letters, 2018
Since the publication of a novel protocol in 1991, cytokine-induced killer (CIK) cells have shown promising results in the treatment against neoplastic diseases. Despite ongoing preclinical and clinical studies, CIK cell treatment in the context of human monoclonal antibodies targeting tumor-necrosis factor receptors remains overlooked.
Kaja D, Biederbick, Ingo G H, Schmidt-Wolf   +1 more
openaire   +3 more sources